JP2020527172A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527172A5 JP2020527172A5 JP2020523047A JP2020523047A JP2020527172A5 JP 2020527172 A5 JP2020527172 A5 JP 2020527172A5 JP 2020523047 A JP2020523047 A JP 2020523047A JP 2020523047 A JP2020523047 A JP 2020523047A JP 2020527172 A5 JP2020527172 A5 JP 2020527172A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disorder
- subject
- epilepsy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 208000035475 disorder Diseases 0.000 claims 9
- 230000001037 epileptic effect Effects 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 206010015037 epilepsy Diseases 0.000 claims 5
- 230000001575 pathological effect Effects 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 claims 3
- 229960003081 probenecid Drugs 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 208000002877 Epileptic Syndromes Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 210000003710 cerebral cortex Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000013560 metabolic epilepsy Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015238 neurotic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305934.6 | 2017-07-13 | ||
| EP17305934.6A EP3427729A1 (en) | 2017-07-13 | 2017-07-13 | Probenecid for use in treating epileptic diseases, disorders or conditions |
| PCT/EP2018/069092 WO2019012109A1 (en) | 2017-07-13 | 2018-07-13 | PROBENECID FOR USE IN THE TREATMENT OF EPILEPTIC DISEASES, DISORDERS OR DISORDERS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527172A JP2020527172A (ja) | 2020-09-03 |
| JP2020527172A5 true JP2020527172A5 (enExample) | 2021-08-12 |
| JP7369693B2 JP7369693B2 (ja) | 2023-10-26 |
Family
ID=59384111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523047A Active JP7369693B2 (ja) | 2017-07-13 | 2018-07-13 | てんかん性の疾患、障害、または病態の処置に使用するためのプロベネシド |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12318358B2 (enExample) |
| EP (2) | EP3427729A1 (enExample) |
| JP (1) | JP7369693B2 (enExample) |
| CN (2) | CN111386107A (enExample) |
| CA (1) | CA3070178A1 (enExample) |
| WO (1) | WO2019012109A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12128034B2 (en) | 2020-03-11 | 2024-10-29 | Iterum Therapeutics International Limited | Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof |
| TWI804037B (zh) * | 2021-11-02 | 2023-06-01 | 長庚醫療財團法人高雄長庚紀念醫院 | 生酮飲食之評估系統及其運作方法 |
| EP4505999A1 (en) | 2023-08-07 | 2025-02-12 | Panntherapi | Probenecid formulations |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US902695A (en) | 1907-12-31 | 1908-11-03 | Stasia B Staley | Package-tie. |
| JPS586027A (ja) | 1981-07-01 | 1983-01-13 | 住友電気工業株式会社 | 高圧ケ−ブルの接続部 |
| GB2104078B (en) | 1981-08-14 | 1985-01-23 | London Polytech | New aminoacid isomers, their production and their medicinal use |
| HUT40447A (en) | 1984-03-29 | 1986-12-28 | Sandoz Ag | Process for preparing substituted alpha-amino acids and pharmaceutical compositions containing such compounds |
| CA1248531A (en) | 1984-04-17 | 1989-01-10 | Jeffrey C. Watkins | 4-substituted piperazine-2-carboxylic acids |
| US4906621A (en) | 1985-05-24 | 1990-03-06 | Ciba-Geigy Corporation | Certain 2-carboxypiperidyl-alkylene phosphonic acids and esters thereof useful for the treatment of disorders responsive to N-methyl-D-aspartate receptor blockade |
| US4746653A (en) | 1986-02-28 | 1988-05-24 | Ciba-Geigy Corporation | Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals |
| US4657899A (en) | 1986-04-09 | 1987-04-14 | Nova Pharmaceutical Corporation | Antagonists of specific excitatory amino acid neurotransmitter receptors |
| IE66149B1 (en) | 1986-09-16 | 1995-12-13 | Novo Nordisk As | Quinoxaline compounds and their preparation and use |
| US4812458A (en) | 1986-09-16 | 1989-03-14 | A/S Ferrosan | 6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical compositions thereof, and their use as neuroleptics |
| US4705781A (en) | 1986-10-08 | 1987-11-10 | Giba-Geigy Corporation | Method of treating cerebral ischemia using 4-(phosphono substituted lower alkyl or lower alkenyl)piperazine-2-carboxylic acids and salts, esters and amides thereof |
| GB8625941D0 (en) | 1986-10-30 | 1986-12-03 | Sandoz Ltd | Substituted alpha-amino acids |
| IL84492A0 (en) | 1986-11-21 | 1988-04-29 | Ciba Geigy Ag | Unsaturated phosphonic acids and derivatives |
| GB8703749D0 (en) | 1987-02-18 | 1987-03-25 | Sandoz Ltd | Piperazinecarboxylic acid |
| US4761405A (en) | 1987-03-04 | 1988-08-02 | Nova Pharmaceutical Corporation | Antagonists of specific excitatory amino acid neurotransmitter receptors having increased potency |
| DK146787A (da) | 1987-03-23 | 1988-09-24 | Ferrosan | Heterocykliske forbindelser, deres fremstilling og anvendelse |
| PH27591A (en) | 1987-08-04 | 1993-08-31 | Ciba Geigy Ag | A process for the manufacture of novel unsaturated amino acid compound |
| GB8719102D0 (en) | 1987-08-12 | 1987-09-16 | Merck Sharp & Dohme | Therapeutic agents |
| US4918064A (en) | 1987-10-21 | 1990-04-17 | G. D. Searle & Co. | Phenyl glycines for use in reducing neurotoxic injury |
| NO179551C (no) | 1987-11-10 | 1996-10-30 | Novo Nordisk As | Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser |
| GB8727792D0 (en) | 1987-11-27 | 1987-12-31 | Merck Sharp & Dohme | Therapeutic agents |
| US4904681A (en) | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
| US4968678A (en) | 1988-02-19 | 1990-11-06 | Eli Lilly And Company | Tetrazole excitatory amino acid receptor antagonists |
| JPH0210544A (ja) | 1988-06-29 | 1990-01-16 | Canon Inc | 光磁気記憶装置 |
| EP0342558B1 (en) | 1988-05-16 | 1994-02-02 | G.D. Searle & Co. | 2-amino-4,5-methyleneadipic acid compounds for treatment of CNS disorders |
| DK160941C (da) | 1988-06-28 | 1991-10-21 | Novo Nordisk As | Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar |
| GB8823605D0 (en) | 1988-10-07 | 1988-11-16 | Merck Sharp & Dohme | Therapeutic agents |
| CA2000901A1 (en) | 1988-10-21 | 1990-04-21 | Alexis A. Cordi | Phosphono-hydroisoquinoline compounds useful in reducing neurotoxic injury |
| DK715888D0 (da) | 1988-12-22 | 1988-12-22 | Ferrosan As | Quinoxalinforbindelser, deres fremstilling og anvendelse |
| DK716188D0 (da) | 1988-12-22 | 1988-12-22 | Ferrosan As | Quinoxalinforbindelser, deres fremstilling og anvendelse |
| US5187171A (en) | 1989-01-09 | 1993-02-16 | G. D. Searle & Co. | Use of a glycine b partial agonist as an antipsychotic |
| US4902695A (en) | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| DE69029668T2 (de) | 1989-03-08 | 1997-08-07 | Merck Sharp & Dohme | Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten |
| US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| US4902687A (en) | 1989-03-27 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| ATE112282T1 (de) | 1989-04-07 | 1994-10-15 | Ciba Geigy Ag | Ungesättigte aminodicarbonsäurederivate. |
| GB8908529D0 (en) | 1989-04-14 | 1989-06-01 | Merck Sharp & Dohme | Therapeutic agents |
| US4960786A (en) | 1989-04-24 | 1990-10-02 | Merrell Dow Pharmaceuticals Inc. | Excitatory amino acid antagonists |
| JPH0347123A (ja) | 1989-05-05 | 1991-02-28 | G D Searle & Co | インドール―２―カルボキシレート化合物類を含有するｃｎｓ疾患治療用組成物 |
| CA2025326C (en) | 1989-09-19 | 2001-04-24 | Jeffrey P. Whitten | Nmda antagonists |
| EP0420806B1 (de) | 1989-09-26 | 1995-07-05 | Ciba-Geigy Ag | Phosphonsäure, Verfahren zur Herstellung und Verwendung als Arzneimittelwirkstoff |
| DK0501378T3 (da) * | 1991-02-28 | 1995-03-20 | Merrell Dow Pharma | NMDA-antagonister |
| ATE162075T1 (de) | 1991-09-09 | 1998-01-15 | Warner Lambert Co | Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält |
| US5318985A (en) * | 1991-12-20 | 1994-06-07 | Merrell Dow Pharmaceuticals Inc. | Potentiation of NMDA antagonists |
-
2017
- 2017-07-13 EP EP17305934.6A patent/EP3427729A1/en not_active Withdrawn
-
2018
- 2018-07-13 CN CN201880059798.3A patent/CN111386107A/zh active Pending
- 2018-07-13 CA CA3070178A patent/CA3070178A1/en active Pending
- 2018-07-13 US US16/630,114 patent/US12318358B2/en active Active
- 2018-07-13 CN CN202510416283.6A patent/CN120478323A/zh active Pending
- 2018-07-13 JP JP2020523047A patent/JP7369693B2/ja active Active
- 2018-07-13 EP EP18739857.3A patent/EP3651758A1/en active Pending
- 2018-07-13 WO PCT/EP2018/069092 patent/WO2019012109A1/en not_active Ceased
-
2025
- 2025-05-30 US US19/223,794 patent/US20250288544A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Andersen et al. | Hypoxic/ischaemic brain damage, especially pallidal lesions, in heroin addicts | |
| Kamble et al. | Tremor syndromes: A review | |
| US11318140B2 (en) | Use of TRPV4 antagonists to ameliorate hydrocephalus and related materials and methods | |
| US9956206B2 (en) | Compositions and methods for treating amyotrophic lateral sclerosis in responders | |
| JP2013534256A5 (enExample) | ||
| JP2020527172A5 (enExample) | ||
| JP2002527474A (ja) | 躁病および双極性障害の治療法 | |
| Hayashida et al. | Aceruloplasminemia with psychomotor excitement and neurological sign was improved by minocycline (case report) | |
| US9968585B2 (en) | Prevention or treatment agent for cerebral amyloid beta storage diseases | |
| Maggi et al. | Parkinsonism in a patient with AIDS and cerebral opportunistic granulomatous lesions | |
| Pang et al. | Treatment of nonconvulsive status epilepticus | |
| Božić et al. | Improvement of post-hypoxic action myoclonus with levetiracetam add-on therapy: a case report | |
| RU2019101210A (ru) | Производное оксазина для применения в предупреждении болезни альцгеймера у пациентов, находящихся в группе риска | |
| Hiraga et al. | Isolated transient myoclonus in the elderly: an under-recognized condition? | |
| Gupta et al. | Levosulpiride: A review | |
| JP2013505264A (ja) | 疼痛制御及び脱髄損傷の回復におけるｎ−２−ヒドロキシ−エチル−ピペラジン−ｎ’−２−エタンスルホン酸（ｈｅｐｅｓ）の役割 | |
| Burke et al. | Refractory symptomatic schizophrenia resulting from frontal lobe lesion: response to clozapine | |
| RU2020106762A (ru) | Применение пробенецида для лечения эпилептических заболеваний, нарушений и состояний | |
| Villagran et al. | 16 Sleep Disorders and Neurocognition | |
| US20190038624A1 (en) | Use of abelson tyrosine kinase inhibitor in treatment of multiple system atrophy | |
| Becker et al. | MRI white matter hyperintensity in neuroleptic malignant syndrome (NMS)—a clue to pathogenesis? | |
| JP2002541224A (ja) | うつ病の治療のためのｇａｂａ類縁体と三環系化合物の組合わせ | |
| CN117338938A (zh) | 用于治疗中枢神经系统紊乱的组合疗法 | |
| US20160367503A1 (en) | Combination Medication for Neuro-Degenerative Diseases | |
| Islam | A review on Donepezil in the treatment of Dementia |